Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplant cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial.

[1]  K. Fleischhauer.  Haplo-PtCy: adjusting the HLA barrier. , 2022, Blood.

[2]  M. Labopin,et al.  Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT , 2022, Bone Marrow Transplantation.

[3]  Shannon R. McCurdy,et al.  HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide. , 2021, Blood.

[4]  Shannon R. McCurdy,et al.  Signatures of GVHD and Relapse after Post-Transplant Cyclophosphamide Revealed by Immune Profiling and Machine Learning. , 2021, Blood.

[5]  V. Rocha,et al.  Outcomes after haploidentical cell transplantation with posttransplant cyclophosphamide: a systematic review and meta-analysis comparing myeloablative with reduced-intensity conditioning regimen and bone marrow with peripheral blood stem-cell graft: PTCy: PBSC or BM and MAC or RIC for Haplo-HCT with , 2021, Transplantation and cellular therapy.

[6]  M. Norkin,et al.  National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Soiffer,et al.  HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. , 2021, Blood.

[8]  M. Solh,et al.  Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. , 2020, Blood advances.

[9]  L. Vago.  Clonal evolution and immune evasion in posttransplantation relapses. , 2019, Hematology. American Society of Hematology. Education Program.

[10]  M. Perales,et al.  Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  B. Shaw.  Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint. , 2017, Blood advances.

[12]  C. Huff,et al.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  P. Thall,et al.  High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation , 2009, Transplantation.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .